Molecular regulation of lymphangiogenesis and targets for tissue oedema

Trends in Molecular Medicine

Volumn 7, Issue 1, 2001, Pages 18-22

  Karkkainen, Marika J ^a   Jussila, Lotta ^a   Alitalo, Kari ^a   Ferrell, Robert E ^b   Finegold, David N ^b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; GLYCOSAMINOGLYCAN; MESSENGER RNA; VASCULOTROPIN;

CELL MEMBRANE PERMEABILITY; ENDOTHELIUM CELL; GENE MUTATION; HOMEOBOX; LYMPH VESSEL ENDOTHELIUM; LYMPHEDEMA; NONHUMAN; REVIEW;

EID: 0034481376     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4914(00)01864-5     Document Type: Review

References (48)

1. The microcirculation and the lymphatic system: Capillary fluid exchange, interstitial fluid and lymph flow
2. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor
3. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines
4. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3
5. Expression of the fm8-like tyrosine kinase FLT4 gene becomes restricted to lymphatic endothelium during development
6. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
7. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)
8. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggest a role in lymphatic vascular development
9. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice
10. VEGF and VEGF-C: Specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane
11. A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities
12. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues
13. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
14. Prox1 function is required for the development of the murine lymphatic system
15. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium
16. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells
17. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan
18. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis
19. Regulation of angiogenesis via vascular endothelial growth factor receptors
20. Mechanisms of angiogenesis and arteriogenesis
21. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain
22. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1
23. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability
24. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development
25. Increased vascularization in mice overexpressing angiopoietin-1
26. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice
27. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
28. Angiopoietin-1 protects the adult vasculature against plasma leakage
29. The inheritance of primary lymphoedema
30. Lymphangiogenesis: Mechanisms, significance and clinical implications
31. Aplasia of superficial lymphatic capillaries in hereditary and connatal lymphedema (Milroy's disease)
32. Diameters of lymphatic capillaries in patients with different forms of primary lymphedema
33. Microlymphatics of human skin
34. Hereditary lymphedema: Evidence for linkage and genetic heterogeneity
35. Phenotypic and genotypic heterogeneity in familial Milroy lymphedema
36. Mapping of primary congenital lymphedema to the 5q35.3 region
37. Missense mutations interfere with VEGFR-3 signaling in primary lymphoedema
38. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase
39. Repeated unbalanced offspring due to a familial translocation involving chromosomes 5 and 6
40. Unbalanced translocation in a mother and her son in one of two 5;10 translocation families
41. A gene for lymphedema-distichiasis maps to 16q24.3
42. Reduction of the genetic interval for lymphoedema-distichiasis to below 2 Mb
43. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome
44. Essential roles of the winged-helix transcription factor MFH-1 in aortic arch patterning and skeletogenesis
45. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q
46. Evidence for a Turner syndrome locus or loci at Xp11.2-p22.1
47. Evidence for circulating bone marrow-derived endothelial cells
48. Lymphangioblasts in the avian wing bud